Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRXNASDAQ:EYENNASDAQ:LUMONASDAQ:NCNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.79+3.0%$3.11$2.30▼$35.60$12.62M1.1567,819 shs19,295 shsEYENEyenovia$1.67+7.7%$1.18$0.85▼$124.80$4.82M0.76416,268 shs487,321 shsLUMOLumos Pharma$4.34$4.34$1.37▼$4.58$37.54M0.7479,835 shsN/ANCNANuCana$0.04-3.8%$0.55$0.03▼$10.79$213K1.6410.41 million shs56.15 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+0.55%+1.10%+14.29%+6.36%-86.57%EYENEyenovia-12.43%-7.19%+42.20%-11.93%-97.28%LUMOLumos Pharma0.00%0.00%0.00%0.00%+77.14%NCNANuCana+2.63%-15.95%-92.91%-95.85%-98.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLRXBioLineRx2.5089 of 5 stars3.34.00.00.02.60.01.3EYENEyenovia1.7748 of 5 stars2.05.00.00.02.80.01.3LUMOLumos PharmaN/AN/AN/AN/AN/AN/AN/AN/ANCNANuCana2.7237 of 5 stars3.32.00.00.03.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 2.50Moderate Buy$26.00586.02% UpsideEYENEyenovia 2.00Hold$2.0019.76% UpsideLUMOLumos Pharma 3.00Buy$8.6398.73% UpsideNCNANuCana 2.50Moderate Buy$25.0066,566.67% UpsideCurrent Analyst Ratings BreakdownLatest NCNA, BLRX, EYEN, and LUMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/2/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/31/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $26.003/21/2025EYENEyenoviaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.44N/AN/A$7.30 per share0.52EYENEyenovia$67.06K71.79N/AN/A$16.32 per share0.10LUMOLumos Pharma$2.21M17.02N/AN/A$3.45 per share1.26NCNANuCanaN/AN/AN/AN/A$8.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$60.61M-$8.80N/AN/AN/A-90.57%-163.37%-34.21%8/15/2025 (Estimated)EYENEyenovia-$27.26M-$58.40N/AN/AN/A-114,639.41%-1,108.24%-139.36%8/11/2025 (Estimated)LUMOLumos Pharma-$34.03M-$4.29N/AN/AN/A-1,583.49%-233.03%-129.88%N/ANCNANuCana-$34.37M-$6.55N/AN/AN/AN/A-314.47%-112.60%8/13/2025 (Estimated)Latest NCNA, BLRX, EYEN, and LUMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million3/20/2025Q4 2024NCNANuCana-$2.43-$0.32+$2.11-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/ALUMOLumos PharmaN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx2.111.521.37EYENEyenovia0.580.740.55LUMOLumos PharmaN/A2.662.66NCNANuCanaN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%EYENEyenovia25.84%LUMOLumos Pharma33.99%NCNANuCana44.00%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%EYENEyenovia7.10%LUMOLumos Pharma25.40%NCNANuCana31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx403.33 million3.29 millionOptionableEYENEyenovia402.88 million1.29 millionOptionableLUMOLumos Pharma308.65 million6.45 millionNot OptionableNCNANuCana305.68 million1.82 millionNot OptionableNCNA, BLRX, EYEN, and LUMO HeadlinesRecent News About These CompaniesNuCana plc: NuCana Prices $7 Million Registered Direct OfferingMay 6, 2025 | finanznachrichten.deEuropean Equities Traded in the US as American Depositary Receipts Drop Sharply in Wednesday TradingApril 30, 2025 | msn.comNuCana plc: NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 22, 2025 | finanznachrichten.deNuCana Reports Q4 EPS GBP (1) vs. GBP (14)March 21, 2025 | markets.businessinsider.comNuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateMarch 20, 2025 | globenewswire.comNuCana Calls for Shareholder Vote on Key ResolutionsMarch 18, 2025 | tipranks.comBank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Tuesday TradingFebruary 25, 2025 | msn.comAurion Biotech Appoints Donald Munoz as Chief Financial OfficerFebruary 10, 2025 | businesswire.comEuropean Equities Traded in the US as American Depositary Receipts Fall in Monday TradingFebruary 3, 2025 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday TradingJanuary 22, 2025 | msn.comNUC-7738 by NuCana for Metastatic Melanoma: Likelihood of ApprovalJanuary 6, 2025 | pharmaceutical-technology.comNUC-7738 by NuCana for T-Cell Lymphomas: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comNUC-7738 by NuCana for Solid Tumor: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comEuropean Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for WeekDecember 13, 2024 | msn.comNuCana Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 25, 2024 | globenewswire.comNuCana’s NUC-3373 Shows Promise in Cancer TreatmentNovember 13, 2024 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Move Higher in Monday TradingNovember 12, 2024 | msn.comNuCana announces initial data from Phase 1b/2 modular study of NUC-3373November 12, 2024 | markets.businessinsider.comNuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or DocetaxelNovember 11, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise FridayOctober 18, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, BLRX, EYEN, and LUMO Company DescriptionsBioLineRx NASDAQ:BLRX$3.79 +0.11 (+2.99%) Closing price 04:00 PM EasternExtended Trading$3.77 -0.02 (-0.55%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Eyenovia NASDAQ:EYEN$1.67 +0.12 (+7.74%) Closing price 04:00 PM EasternExtended Trading$1.71 +0.04 (+2.40%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Lumos Pharma NASDAQ:LUMOLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.NuCana NASDAQ:NCNA$0.04 0.00 (-3.85%) Closing price 04:00 PM EasternExtended Trading$0.04 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
